Advanced search
Publication Cover
Scandinavian Journal of Gastroenterology Volume 56, 2021 - Issue 8
Submit an article Journal homepage
277
Views
7
CrossRef citations to date
0
Altmetric
Original Articles

Irreversible electroporation versus radiofrequency ablation for hepatocellular carcinoma: a single centre propensity-matched comparison

Elliot Freemana Department of Gastroenterology, Alfred Hospital, Melbourne, AustraliaORCID Iconhttps://orcid.org/0000-0001-6841-7679
ORCID Icon,
Wa Cheungb Department of Radiology, Alfred Hospital, Melbourne, Australia
,
Sapphire Ferdousia Department of Gastroenterology, Alfred Hospital, Melbourne, Australia
,
Helen Kavnoudiasb Department of Radiology, Alfred Hospital, Melbourne, Australia
,
Ammar Majeeda Department of Gastroenterology, Alfred Hospital, Melbourne, Australia;c Department of Medicine, Central Clinical School, Monash University, Melbourne, Australia
,
William Kempa Department of Gastroenterology, Alfred Hospital, Melbourne, Australia;c Department of Medicine, Central Clinical School, Monash University, Melbourne, Australia
&
Stuart K. Robertsa Department of Gastroenterology, Alfred Hospital, Melbourne, Australia;c Department of Medicine, Central Clinical School, Monash University, Melbourne, AustraliaCorrespondence[email protected]
 show all
Pages 942-947 | Received 21 Feb 2021, Accepted 07 May 2021, Published online: 30 May 2021

References

  • Ferlay J, Colombet M, Soerjomataram I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144(8):1941–1953.
  • Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
  • The Lancet. GLOBOCAN 2018: counting the toll of cancer. Lancet. 2018;392(10152):985.
  • Kemp W, Pianko S, Nguyen S, et al. Survival in hepatocellular carcinoma: impact of screening and etiology of liver disease. J Gastroenterol Hepatol. 2005;20(6):873–881.
  • Bruix J, Llovet JM. Major achievements in hepatocellular carcinoma. Lancet. 2009;373(9664):614–616.
  • Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391(10127):1301–1314.
  • Galle PR, Forner A, Llovet JM, et al. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236.
  • Lencioni R, Crocetti L. Local-regional treatment of hepatocellular carcinoma. Radiology. 2012;262(1):43–58.
  • Cho YK, Kim JK, Kim MY, et al. Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies. Hepatology. 2009;49(2):453–459.
  • Zimmerman A, Grand D, Charpentier KP. Irreversible electroporation of hepatocellular carcinoma: patient selection and perspectives. JHC. 2017;4:49–58.
  • Freeman E, Cheung W, Kavnoudias H, et al. Irreversible electroporation for hepatocellular carcinoma: longer-term outcomes at a single centre. Cardiovasc Intervent Radiol. 2021;44(2):247–253.
  • Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018;68(2):723–750.
  • Cheung W, Kavnoudias H, Roberts S, et al. Irreversible electroporation for unresectable hepatocellular carcinoma: initial experience and review of safety and outcomes. Technol Cancer Res Treat. 2013;12(3):233–241.
  • Ball C, Thomson KR, Kavnoudias H. Irreversible electroporation. Anesthesia Analgesia. 2010;110(5):1305–1309.
  • Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30(01):052–060.
  • Zhang B, Yang Y, Ding L, et al. Tumor ablation enhancement by combining radiofrequency ablation and irreversible electroporation: an in vitro 3D tumor study. Ann Biomed Eng. 2019;47(3):694–705.
  • Sugimoto K, Kakimi K, Takeuchi H, et al. Irreversible electroporation versus radiofrequency ablation: comparison of systemic immune responses in patients with hepatocellular carcinoma. J Vasc Interv Radiol. 2019;30(6):845–853.e6.
  • Verloh N, Jensch I, Lürken L, et al. Similar complication rates for irreversible electroporation and thermal ablation in patients with hepatocellular tumors. Radiol Oncol. 2019;53(1):116–122.
  • Bulvik BE, Rozenblum N, Gourevich S, et al. Irreversible electroporation versus radiofrequency ablation: a comparison of local and systemic effects in a small-animal model. Radiology. 2016;280(2):413–424.
  • Narayanan G, Froud T, Lo K, et al. Pain analysis in patients with hepatocellular carcinoma: irreversible electroporation versus radiofrequency ablation—initial observations. Cardiovasc Inter Rad. 2013;36(1):176–182.
  • Cannon R, Ellis S, Hayes D, et al. Safety and early efficacy of irreversible electroporation for hepatic tumors in proximity to vital structures. J Surg Oncol. 2013;107(5):544–549.
  • Scheffer HJ, Nielsen K, Jong M. d, et al. Irreversible electroporation for nonthermal tumor ablation in the clinical setting: a systematic review of safety and efficacy. J Vasc Interv Radiol. 2014;25(7):997–1011.
  • Niessen C, Igl J, Pregler B, et al. Factors associated with short-term local recurrence of liver cancer after percutaneous ablation using irreversible electroporation: a prospective single-center study. J Vasc Interv Radiol. 2015;26(5):694–702.
  • Chan P, McLean C, Chan S, et al. The interaction between irreversible electroporation therapy (IRE) and embolization material using a validated vegetal model: an experimental study. Diagn Interv Radiol. 2019;25(4):304–309.
  • Bhutiani N, Philips P, Scoggins CR, et al. Evaluation of tolerability and efficacy of irreversible electroporation (IRE) in treatment of Child-Pugh B (7/8) hepatocellular carcinoma (HCC). Hpb. 2016;18(7):593–599.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.